On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.

On the news front, the company announced on September 17 that the NMPA's Center for Drug Evaluation has accepted the registration application for transferring Velsipity (etrasimod) production from overseas to domestic facilities, with the application included in the priority review program. Local production is expected to commence in 2027 with annual capacity of up to 50 million tablets, enhancing supply chain resilience and cost efficiency across China and Asia-Pacific markets.

Additionally, multiple positive catalysts have converged in recent weeks. The company's first cardiovascular drug Xinbituo was approved by NMPA in early September for acute PSVT treatment in adults, marking the first and only innovative therapy for this indication in over 30 years. The company reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profits turning positive. The chairman of the board also recently increased his holdings, reinforcing market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)